MannKind Corporation
MNKDMannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991.
Drugs in Pipeline
15
Phase 3 Programs
8
Upcoming Catalysts
3
Next Catalyst
Aug 5, 2026
27dMarket Overview
Stock performance and key metrics
3 upcoming, 2 past
How MNKD's past catalysts played out
Metformin & Secretagogues
Diabetes Mellitus, Type 2
Technosphere® Insulin with MedTone C Inhaler
Type 1 Diabetes Mellitus
Usual Care
Diabetes, Type 1
70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Diabetes Type 2
Technosphere® Insulin
Type 2 Diabetes
Active comparator
Diabetes, Type I
Technosphere Insulin
Type 2 Diabetes Mellitus
Afrezza
Diabetes Mellitus, Type 1
Basal insulin
Type 1 Diabetes Mellitus
Technosphere/Insulin
Diabetes Mellitus, Type 2
Actrapid
Type 2 Diabetes Mellitus
MKC1106-MT
Melanoma (Skin)
Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Type 2 Diabetes Mellitus
Technosphere® Insulin Inhalation Powder
Diabetes Mellitus: Type 1
Technosphere Insulin Inhalation Powder
Diabetes Type 2
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Metformin & Secretagogues | Phase 3 | Diabetes Mellitus, Type 2 | - | - |
Technosphere® Insulin with MedTone C Inhaler | Phase 3 | Type 1 Diabetes Mellitus | - | - |
Usual Care | Phase 3 | Diabetes, Type 1 | - | - |
70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin) | Phase 3 | Diabetes Type 2 | - | - |
Technosphere® Insulin | Phase 3 | Type 2 Diabetes | - | - |
Active comparator | Phase 3 | Diabetes, Type I | - | - |
Technosphere Insulin | Phase 3 | Type 2 Diabetes Mellitus | - | - |
Afrezza | Phase 3 | Diabetes Mellitus, Type 1 | - | - |
Basal insulin | Phase 2 | Type 1 Diabetes Mellitus | - | - |
Technosphere/Insulin | Phase 2 | Diabetes Mellitus, Type 2 | - | - |
Actrapid | Phase 2 | Type 2 Diabetes Mellitus | - | - |
MKC1106-MT | Phase 2 | Melanoma (Skin) | - | - |
Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler | Phase 2 | Type 2 Diabetes Mellitus | - | - |
Technosphere® Insulin Inhalation Powder | Phase 2 | Diabetes Mellitus: Type 1 | - | - |
Technosphere Insulin Inhalation Powder | Phase 2 | Diabetes Type 2 | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in MannKind Corporation's drug pipeline?→
CatalystAlert tracks 15 drug candidates in MannKind Corporation's (MNKD) pipeline across Phase 3, Phase 2. Its lead program is Metformin & Secretagogues (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is MannKind Corporation's next FDA catalyst?→
MannKind Corporation's (MNKD) next tracked catalyst is a Earnings expected August 5, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MNKD biotech catalysts?→
Add MNKD to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow MannKind Corporation's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.